

DAFTAR PUSTAKA

1. Lamar ZS, Dothard A, Kennedy LA, Isom S, Robinson M, Vaidya R, et al. Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration—a retrospective study. *Leuk Lymphoma*. 2018;59(8).
2. Brunello A, Kapoor R, Extermann M. Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. *Am J Clin Oncol Cancer Clin Trials*. 2011;34(3).
3. Tamez-Pérez HE. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. *World J Diabetes*. 2015;6(8).
4. Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, et al. Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research Network. *Br J Cancer*. 2015 Apr;112(9):1575–84.
5. Stathis A, Owens C. Risk factors, etiology, and pathogenesis. 2016;
6. Nogai H, Dörken B, Lenz G. Pathogenesis of Non-Hodgkin’s Lymphoma. *J Clin Oncol*. 2011 May;29(14):1803–11.
7. Bujoreanu I, Gupta V. Anatomy, Lymph Nodes. *StatPearls*. 2021.
8. Parham P, Janeway C. *The immune system* 3rd Edition. New York: Garland Science; 2009.
9. Ozdowski L, Gupta V. Physiology, Lymphatic System. *StatPearls*. 2021.
10. Mugnaini EN, Ghosh N. Lymphoma. *Prim Care Clin Off Pract*. 2016 Dec;43(4):661–75.
11. Matasar MJ, Zelenetz AD. Overview of Lymphoma Diagnosis and

- Management. *Radiol Clin North Am.* 2008 Mar;46(2):175–98.
12. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood.* 2016 May;127(20):2375–90.
 13. Jamil A, Mukkamalla SKR. Lymphoma. *StatPearls.* 2021.
 14. Nair R, Kakroo A, Bapna A, Gogia A, Vora A, Pathak A, et al. Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group. *Indian J Hematol Blood Transfus.* 2018 Jul;34(3):398–421.
 15. Yahanda AM. *Surgical Treatment: Evidence-Based and Problem-Oriented.* Munich: Zuckschwerdt; 2001.
 16. Duncan N. *Lymphomas: current and future treatment options.* 2014;
 17. Kane EV, Bernstein L, Bracci PM, Cerhan JR, Costas L, Dal Maso L, et al. Postmenopausal hormone therapy and non-Hodgkin lymphoma: a pooled analysis of InterLymph case-control studies. *Ann Oncol.* 2013 Feb;24(2):433–41.
 18. Chung C. Current targeted therapies in lymphomas. *Am J Heal Pharm.* 2019 Oct;76(22):1825–34.
 19. Giacco F, Brownlee M. Oxidative Stress and Diabetic Complication. *Circ Res.* 2011;107(9):1058–70.
 20. Folli F, Corradi D, Davalli A, Paez A, Giaccari A, Perego C, et al. The Role of Oxidative Stress in the Pathogenesis of Type 2 Diabetes Mellitus Micro- and Macrovascular Complications: Avenues for a Mechanistic-Based Therapeutic Approach. *Curr Diabetes Rev.* 2011;7(3):313–24.
 21. Kwon S, Hermayer KL. Glucocorticoid-Induced Hyperglycemia. *Am J Med Sci [Internet].* 2013;345(4):274–7. Available from:

<http://dx.doi.org/10.1097/MAJ.0b013e31828a6a01>

22. Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. *Diabetes Metab Res Rev.* 2014;30(2):96–102.
23. Mor A, Dekker OM, Nielsen JS, Nielsen HB, Sorensen HT. Impact of Glycemic Control on Risk of Infections in Patients with Type 2 Diabetes: A population-based cohort study. *Am J epidemiol.* 2017;186(2):227–36.
24. Turina M, Fry DE. Acute hyperglycemia and innate immune system cellular, and molecular aspect. *Crit Care Med.* 2005;33(7):1–10.
25. Mauriello CT, Hair PS, Rohn RD, Rister NS, Krishna NK, Cunnion KM. Hyperglycemia Inhibits Complement-Mediated Immunological Control of *S.aureus* in a Rat Model of Peritonitis. *J Diabetes Res.* 2014;2014:1–11.
26. Yang C, Wang Z, Hu Y, Yang S, Cheng F, Rao J, et al. Hyperglycemia-triggered ATF6-CHOP pathway aggravates acute inflammatory liver injury by β -catenin signaling. *Cell Death Discov.* 2022;8(115):1–10.
27. Marić A, Miličević T, Lončar JV, Galušić D, Radman M. Patterns of glucose fluctuation are challenging in patients treated for non-Hodgkin's lymphoma. *Int J Gen Med.* 2020;13.